Research programme: human monoclonal antibodies - Takeda/Kirin BreweryAlternative Names: Human monoclonal antibodies research programme - Takeda/Kirin
Latest Information Update: 30 Jun 2011
At a glance
- Originator Kirin Brewery; Takeda
- Class Monoclonal antibodies; Monoclonal antibody diagnostics
- Mechanism of Action Diagnostic imaging enhancers; Immunomodulators
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
On Fast track
Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.
Highest Development Phases
- No development reported Unspecified
Most Recent Events
- 19 Jan 2007 No development reported - Preclinical for Undefined indication in Japan (unspecified route)
- 19 Jan 2007 No development reported - Preclinical for Undefined indication (diagnosis) in Japan (unspecified route)
- 07 Aug 2003 Preclinical trials in Undefined indication in Japan (unspecified route)